Jane Street Group LLC Has $293,000 Stock Position in Agenus Inc. (NASDAQ:AGEN)

Jane Street Group LLC decreased its stake in Agenus Inc. (NASDAQ:AGEN) by 42.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 53,490 shares of the biotechnology company’s stock after selling 39,153 shares during the period. Jane Street Group LLC’s holdings in Agenus were worth $293,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Point72 DIFC Ltd acquired a new stake in shares of Agenus in the second quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus in the second quarter worth $106,000. HighTower Advisors LLC grew its stake in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Agenus by 52.0% in the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 9,422 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after acquiring an additional 9,731 shares during the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Agenus currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Agenus Price Performance

Shares of AGEN stock opened at $3.12 on Friday. The stock has a market cap of $73.19 million, a P/E ratio of -0.28 and a beta of 1.27. Agenus Inc. has a one year low of $2.50 and a one year high of $19.69. The stock has a fifty day moving average price of $3.22 and a 200 day moving average price of $5.83.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.